Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807269 | 0.76 | TTR (0.38) | — | |
| SCHEMBL14872338 | 0.75 | CYP1A1 (0.33) | CYP1A1CYP1B1HDAC8 | |
| SCHEMBL11223385 | 0.74 | LMNA (0.38) | HDAC8 | |
| SCHEMBL31308675 | 0.74 | ALDH1A1 (0.45) | CYP1A1CYP1B1HDAC8 | |
| SCHEMBL29149085 | 0.71 | PDE3B (0.35) | HDAC8 | |
| SCHEMBL11985992 | 0.71 | ALDH1A1 (0.47) | — | |
| SCHEMBL15345779 | 0.70 | CYP1A1 (0.33) | CYP1A1CYP1B1HDAC8 | |
| SCHEMBL20929228 | 0.70 | ALDH1A1 (0.50) | CYP1A1CYP1B1 | |
| SCHEMBL279564 | 0.69 | CYP1A2 (0.44) | — | |
| SCHEMBL12889907 | 0.69 | EIF4A3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | CYP1A1 700/4885CYP1B1 623/4885HDAC8 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.